Chelliah Malcolm P, Zinn Zachary, Khuu Phoung, Teng Joyce M C
School of Medicine, Stanford University, Stanford, CA, USA.
Department of Dermatology, West Virginia University, Morgantown, WV, USA.
Pediatr Dermatol. 2018 Jul;35(4):e224-e227. doi: 10.1111/pde.13545. Epub 2018 May 22.
Epidermolysis bullosa is a rare blistering skin disorder that is challenging to manage because skin fragility and repeated wound healing cause itching, pain, limited mobility, and recurrent infections. Cannabidiol, an active cannabinoid found in cannabis, is postulated to have antiinflammatory and analgesic effects. We report 3 cases of self-initiated topical cannabidiol use in patients with epidermolysis bullosa in an observational study. One patient was weaned completely off oral opioid analgesics. All 3 reported faster wound healing, less blistering, and amelioration of pain with cannabidiol use. Although these results demonstrate promise, further randomized, double-blind clinical trials are necessary to provide scientific evidence of our observed benefits of cannabidiol for the treatment of epidermolysis bullosa.
大疱性表皮松解症是一种罕见的水疱性皮肤病,由于皮肤脆弱和反复伤口愈合会导致瘙痒、疼痛、活动受限和反复感染,因此治疗具有挑战性。大麻二酚是大麻中发现的一种活性大麻素,据推测具有抗炎和镇痛作用。在一项观察性研究中,我们报告了3例大疱性表皮松解症患者自行使用外用大麻二酚的病例。一名患者完全停用了口服阿片类镇痛药。所有3例患者均报告使用大麻二酚后伤口愈合加快、水疱减少且疼痛改善。尽管这些结果显示出了前景,但仍需要进一步的随机双盲临床试验,以提供科学证据证明我们观察到的大麻二酚对大疱性表皮松解症治疗的益处。